Fluzoparib Capsules are a type of PARP (Poly(ADP-ribose) polymerase) inhibitor, primarily indicated for the treatment of malignant tumors such as specific types of advanced ovarian cancer and prostate cancer. The medication must be used in strict accordance with a physician’s advice, with key focus on dosage administration, monitoring of adverse reactions, contraindications and drug interactions.
Dosage and Administration Guidelines
Take as directed by a physician
The dosage shall be adjusted based on the patient’s physical condition, disease state and treatment phase, and must not be increased, decreased or discontinued without medical approval.
Administration time
Oral administration is generally at a fixed time each day; whether to take on an empty stomach shall follow the product instructions or the physician’s guidance.
Missed dose management
If a dose is missed, a makeup dose is not recommended. Continue the medication as scheduled and consult a physician promptly.
Adverse Reactions and Monitoring
Common reactions
Including anemia, nausea, fatigue, thrombocytopenia and other symptoms, most of which are mild or moderate in severity.
Hematological monitoring
Routine blood tests must be performed regularly. In case of severe anemia or thrombocytopenia, suspend the medication and seek medical attention immediately.
Other symptoms
Dyspnea, severe allergic reactions (e.g., rash, edema) and other severe symptoms require immediate discontinuation of the medication and emergency medical treatment.
Contraindications and Precautions
Hypersensitivity contraindication
Prohibited for patients with hypersensitivity to any component of this drug.
Pregnancy and lactation
This drug may impair fetal development. Strict contraceptive measures must be taken during medication, and breastfeeding shall be suspended for lactating women.
Hepatic and renal insufficiency
Use with extreme caution in patients with moderate to severe hepatic or renal insufficiency; dosage adjustment shall be made only after a comprehensive evaluation by a physician.
Drug Interactions
CYP3A inhibitors/inducers
Drugs such as clarithromycin and rifampicin may alter the efficacy of fluzoparib. Patients must inform their physicians of all medications currently being taken.
Anticoagulants
Concomitant use with anticoagulants may increase the risk of bleeding; close monitoring of coagulation function is required in such cases.
Storage and General Precautions
Storage conditions
Store in a sealed container, protected from light, at a temperature below 25℃. Keep out of the reach of children to prevent accidental ingestion.
Long-term medication
Regular reexaminations including imaging tests and tumor marker detections must be conducted to assess treatment efficacy.
Note: Fluzoparib is a prescription-only drug. The specific medication regimen shall be formulated based on clinical diagnosis. In case of abnormal symptoms or changes in disease status during treatment, patients shall have a follow-up consultation in a timely manner for adjustment of the treatment plan.
